Massachusetts Financial Services Co. MA Has $170.61 Million Position in Eli Lilly and Company $LLY

Massachusetts Financial Services Co. MA lessened its stake in Eli Lilly and Company (NYSE:LLY) by 73.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 218,858 shares of the company’s stock after selling 617,976 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Eli Lilly and Company were worth $170,606,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in LLY. Lazard Freres Gestion S.A.S. boosted its position in shares of Eli Lilly and Company by 114.3% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after purchasing an additional 41,222 shares in the last quarter. Precedent Wealth Partners LLC increased its position in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after buying an additional 39 shares in the last quarter. Capital Advisors Inc. OK raised its stake in Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after buying an additional 429 shares during the period. Family CFO Inc bought a new position in Eli Lilly and Company in the second quarter worth approximately $54,000. Finally, Duquesne Family Office LLC boosted its holdings in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after acquiring an additional 32,640 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on LLY. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Loop Capital set a $950.00 price target on shares of Eli Lilly and Company in a research report on Monday, November 10th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Guggenheim reaffirmed a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Finally, UBS Group lifted their price objective on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a report on Friday, November 7th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.11.

Eli Lilly and Company Price Performance

LLY opened at $1,024.67 on Monday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,033.62. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market capitalization of $968.70 billion, a price-to-earnings ratio of 66.97, a P/E/G ratio of 1.21 and a beta of 0.43. The firm’s fifty day moving average price is $826.89 and its two-hundred day moving average price is $779.30.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the company posted $1.18 earnings per share. The firm’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.